Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 2/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6363695 | 0.89 | TAAR1 (0.35) | TAAR1SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL29284007 | 0.82 | TAAR1 (0.30) | TAAR1SYKAURKB | |
| SCHEMBL881080 | 0.82 | SLC6A2 (0.40) | TAAR1SYKAURKBSLC6A2SLC6A4 | |
| SCHEMBL1251228 | 0.80 | CA1 (0.40) | TAAR1SYKAURKBSLC6A2SLC6A4 | |
| SCHEMBL782154 | 0.80 | TAAR1 (0.31) | TAAR1SYKAURKBSLC6A2SLC6A4 | |
| SCHEMBL6369928 | 0.80 | TAAR1 (0.31) | TAAR1SYKAURKBSLC6A2SLC6A4 | |
| SCHEMBL11370385 | 0.80 | SLC6A2 (0.33) | TAAR1SYKAURKBSLC6A2SLC6A4 | |
| SCHEMBL3834227 | 0.80 | CA1 (0.40) | TAAR1SYKAURKBSLC6A2SLC6A4 | |
| SCHEMBL2200907 | 0.79 | SLC6A2 (0.33) | TAAR1SYKAURKBSLC6A2SLC6A4 | |
| SCHEMBL2921380 | 0.78 | CYP2D6 (0.44) | TAAR1SYKAURKBSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084902-A | 2-Aminothiazole pyrimidopyridone compound or pharmaceutically acceptable salt or stereoisomer, preparation method and application | 赣南师范大学 | 2024-05-28 | — | — | CN | claimed |
| CN-117794923-A | Benzodioxane compound, and preparation method and application thereof | 南京红云生物科技有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-115916759-A | Substituted quinazoline compound, preparation method, pharmaceutical composition and application thereof | 南京红云生物科技有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-115697996-A | Alkenyl pyrimidine compound, preparation method and application thereof | 南京红云生物科技有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-114728009-A | Preventing or treating diseases and disorders associated with tissue damage | 李晓祥 | 2022-07-08 | — | — | CN | claimed |
| CN-113717156-A | EGFR inhibitor, preparation method and application thereof | 南京红云生物科技有限公司 | 2021-11-30 | — | — | CN | claimed |
| CN-110914267-A | Pyrimidopyridone or pyridopyridone compound and application thereof | 江苏奥赛康药业有限公司 | 2020-03-24 | — | — | CN | claimed |
| CN-110869369-A | Five-membered and six-membered nitrogen heteroaromatic ring compound, preparation method thereof, medicinal composition and application thereof | 厦门大学 | 2020-03-06 | — | — | CN | claimed |
| CN-118084902-A | 2-Aminothiazole pyrimidopyridone compound or pharmaceutically acceptable salt or stereoisomer, preparation method and application | 赣南师范大学 | 2024-05-28 | — | — | CN | disclosed |
| CN-117794923-A | Benzodioxane compound, and preparation method and application thereof | 南京红云生物科技有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-116239597-A | Pyrimidine pyrrole derivative and medicinal composition and application thereof | 中国科学院上海药物研究所 | 2023-06-09 | — | — | CN | disclosed |
| CN-113717156-B | EGFR inhibitor, preparation method and application thereof | 南京红云生物科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-115916759-A | Substituted quinazoline compound, preparation method, pharmaceutical composition and application thereof | 南京红云生物科技有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115697996-A | Alkenyl pyrimidine compound, preparation method and application thereof | 南京红云生物科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-113717156-A | EGFR inhibitor, preparation method and application thereof | 南京红云生物科技有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-107151250-B | Pyrimidine seven-membered ring compound, preparation method thereof, medicinal composition and application thereof | 安徽省新星药物开发有限责任公司 | 2020-03-27 | — | — | CN | disclosed |
| CN-110914267-A | Pyrimidopyridone or pyridopyridone compound and application thereof | 江苏奥赛康药业有限公司 | 2020-03-24 | — | — | CN | disclosed |
| CN-110869369-A | Five-membered and six-membered nitrogen heteroaromatic ring compound, preparation method thereof, medicinal composition and application thereof | 厦门大学 | 2020-03-06 | — | — | CN | disclosed |
| WO-2005016925-A1 | AZAQUINAZOLINE DERIVATIVES | PFIZER LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038047-A1 | Azaquinazoline derivatives | EDWARDS PAUL JOHN (GB) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038047-A1 | Azaquinazoline derivatives | AZI2, P2RX5, P2RX7 | TAAR1 2677/4885SYK 1852/4885AURKB 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.